Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270
June 13, 2017 16:30 ET | Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office...
Sucampo Reports First Quarter 2017 Financial Results
May 03, 2017 06:30 ET | Sucampo Pharmaceuticals Inc
Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 03, 2017 (GLOBE...
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1
April 18, 2017 06:30 ET | Sucampo Pharmaceuticals Inc
ROCKVILLE, Md., April 18, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the publication of a new study in an...
Sucampo Acquires Vtesse Inc.
April 03, 2017 06:30 ET | Sucampo Pharmaceuticals Inc
Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...